Form D · Other
Montlake Bioscience Inc.
Las Vegas, NV · CIK 0001757681
Offering snapshot reported Nov 1, 2018 · SEC filing
- Reported sold
- $11.3M Offering amount: $25M
- Investors reported
- 8 Form D · investor count
- Minimum accepted
- $250K Reported outside-investor minimum
- First sale
- Oct 19, 2018 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 1, 2018 | Initial | $11,349,624 | No comparison | 8 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-324837
Series A Preferred Stock
Source: Form D, filed Nov 1, 2018. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Baxter Baldwin | Director |
| Pete Findley | Director |
| Jeremy Kiefer | Executive |
Issuer details
Industry: Other (See others in industry)
Address:
222 Karen Ave #3807
Las Vegas, NV, 89109
Las Vegas, NV, 89109